Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
Yahoo Finance host Josh Lipton breaks down the day's top trending stocks and market stories in the Market Minute. AbbVie ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which she experienced when taking opioids.
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigin ...